Chronic lymphocytic leukemia: a clinical review including Korean cohorts.
- Author:
Young Woo JEON
1
;
Seok Goo CHO
Author Information
- Publication Type:Review
- Keywords: Leukemia, lymphocytic, chronic, B-cell; Incidence; Investigational new drug application; Korean cohort
- MeSH: Antigens, Surface; B-Lymphocytes; Biology; Cohort Studies*; Disease-Free Survival; Incidence; Investigational New Drug Application; Leukemia, Lymphocytic, Chronic, B-Cell*; Lymphocytosis; Pathology, Molecular; Phosphatidylinositol 3-Kinase; Protein-Tyrosine Kinases; Splenomegaly
- From:The Korean Journal of Internal Medicine 2016;31(3):433-443
- CountryRepublic of Korea
- Language:English
- Abstract: Only 5th decade ago, chronic lymphocytic leukemia (CLL) was only recognized as disease group of presenting features like peripheral lymphocytosis, organomegaly including of splenomegaly. As understanding of disease biology and molecular diagnostic tools are getting improved gradually, characterization of variation in CLL's clinical courses was facilitated, resulting in better risk stratification and targeted treatments. Consequently multiple new targeted agents have been used in treatment of CLL, it makes improved clinical outcome. Rituximab containing chemoimmunotherapy (combination of rituximab, fludarabine, and cyclophosphamide) have shown better overall response rate and progression-free survival on fit patients' group in front-line setting, result in standard first-line therapeutic option for CLL. Furthermore, after introducing that the B-cell receptor is crucial for the evolution and progression of CLL, emerging treatments targeting highly activated surface antigens and oncogenic signaling pathways have been associated with several successes in recent decades. These include new anti-CD 20 monoclonal antibody (obinutuzumab), the bruton tyrosine kinase inhibitor (ibrutinib), the phosphatidylinositol 3-kinase inhibitor (idelalisib), and B-cell CLL/lymphoma 2 inhibitor (ABT-199 and ABT-263). So, we discuss not only general pathophysiology of CLL, but also rapidly advancing treatment strategies that are being studied or approved for treatment of CLL.
